Dr. Wolfson has over twenty five years of experience of working in academic and industrial environment on various aspects of nucleic acid biochemistry, assay development, and practical applications of nucleic acid technologies, including RNAi, and tumor immunology. Prior to MirImmune Dr. Wolfson founded Advirna, an RNAi technology company,. developing RNAi delivery technologies as research tools. Alexey’s team at Advirna has developed a proprietary algorithm and streamlined screening process that allows rapid generation of RNAi lead compounds against a broad range of targets. This research has laid the basis for MirImmune’s silencing technology. Dr Wolfson has authored over 30 peer-reviewed papers and several book chapters.
